Stargardt disease

eyeball eye disease eyelash eyes

Biotech

Despite ph. 3 miss, Alkeus sees path forward for eye disease med

Despite a phase 3 miss, Alkeus still sees a path forward for its oral eye disease asset.

Gabrielle Masson Sep 17, 2024 10:58am

Image of the ocean

Ascidian Therapeutics rises from ATP's ocean floor with $50M

Oct 12, 2022 11:34am

Eye

Belite Bio hits go on IPO to fund late-phase vision loss trials

Apr 6, 2022 8:30am